MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS Article

Bell, Erica H, Zhang, Peixin, Fisher, Barbara J et al. (2016). MPTH-41. MGMT STATUS PREDICTS SURVIVAL OUTCOMES IN NRG ONCOLOGY/RTOG 0424: A PHASE II TRIAL OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY FOR HIGH RISK LOW-GRADE GLIOMAS . NEURO-ONCOLOGY, 18(suppl_6), vi115-vi115. 10.1093/neuonc/now212.478

cited authors

  • Bell, Erica H; Zhang, Peixin; Fisher, Barbara J; Macdonald, David R; McElroy, Joseph P; Lesser, Glenn J; Fleming, Jessica; Chakraborty, Arup; Liu, Ziyan; Becker, Aline Paixao; Fabian, Denise; Aldape, Kenneth D; Ashby, Lynn S; Werner-Wasik, Maria; Walker, Eleanor M; Bahary, Jean-Paul; Kwok, Young; Yu, Michael; Laack, Nadia N; Schultz, Christopher J; Gray, Heidi J; Robins, H Ian; Mehta, Minesh P; Chakravarti, Arnab

authors

publication date

  • November 1, 2016

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Health Disparities
  • Minority Health
  • Neurosciences
  • Precision Medicine
  • Radiation Oncology
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • vi115

end page

  • vi115

volume

  • 18

issue

  • suppl_6